Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $450

Benzinga Newsdesk www.benzinga.com Negative 86.6%

Neg 86.6% Neu 0% Pos 0%

Barclays analyst Eliana Merle maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $527 to $450.